搜尋結果 "#nivolumab"

動態

查看更多結果

Mary Grace N. Tamio shared news

在 September 10 2023 at 06:05 PM 已編輯

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma

#ipilimumab #nivolumab #adrenocorticalcarcinoma #journals #articles

More info | ⬇️

Case Report: Response to ipilimumab and nivolumab in a patient with adrenocortical carcinoma
BackgroundAdrenocortical carcinoma (ACC) is a rare malignancy with limited treatment options. The evidence for the use of ...
0 0 0 0 0 0 0

留言

Like

分享
Mary Grace N. Tamio shared news

在 August 08 2022 at 11:30 PM 已編輯

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy

#nivolumab #fluoropyrimidine #chemotherapy #journals #articles

For more information | ⬇️

Nivolumab approved for combination with fluoropyrimidine- and platinum-based combination chemotherapy
Nivolumab has recently been approved both in combination with fluoropyrimidine- and platinum-based combination chemotherap...
0 0 0 0 0 0 0

留言

Like

分享
Mary Grace N. Tamio shared news

在 June 25 2022 at 07:26 PM 已編輯

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression

#nivolumab #tcelllymphoma #hyperprogression #journals #articles

For more information | ⬇️

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
IntroductionPeripheral T-cell lymphomas (PTCL) are a heterogeneous group of mature aggressive T-cell non-Hodgkin’s lymphom...
0 0 0 0 0 0 0

留言

Like

分享
Mary Grace N. Tamio

在 January 06 2022 at 03:40 PM 已編輯

Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma

#relatimab #nivolumab #melanoma

For more information | ⬇️
https://cn1699.com/news/relatlimab-plus-nivolumab-improves-progression-free-survival-metastatic-melanoma

Relatlimab plus nivolumab improves progression-free survival in metastatic melanoma | CN1699
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and nivolumab doubled the...
0 0 0 0 0 0 0

留言

Like

分享
Mary Grace N. Tamio shared news

在 August 22 2021 at 05:41 PM 已編輯

Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases

#cemiplimab #nivolumab #myastheniagravis #journals #articles

For more information |⬇️

Cemiplimab- and nivolumab-induced myasthenia gravis: two clinical cases
Immune-related myasthenia gravis is a rare, disabling, and potentially fatal adverse event of immune checkpoint inhibitor ...
0 0 0 0 0 0 0

留言

Like

分享

搜尋過濾器

搜尋結果 "#nivolumab"

動態